Fundraising Fox
/Companies
Sign in

Amphix Bio

Chicago, US · Delaware corporation

Find your way into Amphix Bio

Sign up to see every warm intro you have to Amphix Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Amphix Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Amphix Bio develops peptide therapeutics based on a supramolecular chemistry platform that forms nanostructure scaffolds to activate regenerative signaling in cells and tissues. Its pipeline targets neurological injuries, neuro-inflammatory diseases, and musculoskeletal disorders.

BiotechDeep Tech

Founders & leadership

SS
Samuel StuppCo-founder & Chief Scientific Officer
NSNick Sather
Nick SatherCo-founder & Chief Executive OfficerCo-founder and Chief Executive Officer of Amphix Bio, which develops peptide therapeutics for regenerative medicine targeting neurological and musculoskeletal disorders.
DG
Dévora GrynspanCo-founder, Board Observer & Secretary

Board

KW
Kok-Wai WongBoard director
SR
Stephen R WilsonBoard director
JP
John PotocsnakBoard director

Reported raises · per SEC filings

Form D private placements

$10.3M disclosed across 1 round · 2025

▶$10.3MraisedDec 2025 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Samuel StuppExecutive Officer, Director
  • Kok-Wai WongDirector
  • Stephen R WilsonDirector
  • John PotocsnakDirector
  • Nicholas SatherExecutive Officer, Director
Offering amount
$12.5M
Amount sold
$10.3M
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
PhigenixPhigenix develops personalized medicine for cancer, including companion diagnostics and targeted therapies for prostate and breast cancer patients. Its work centers on early detection and targeted inhibition of PAX2 and EN2 oncogenes and a cancer vaccine using Human Beta Defensin-1 (DEFB1) mRNA to direct the immune system against cancer cells.

Companies working in the same space as Amphix Bio.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase I2022$252.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Amphix Bio raises $12.5M seed round to advance peptide drug platformprnewswire.com · Dec 2025Amphix Bio lands federal and state grants to manufacture regenerative therapies - BioSpacebiospace.com · Nov 2024

Frequently asked questions

What does Amphix Bio do?
Amphix Bio develops peptide therapeutics based on a supramolecular chemistry platform that forms nanostructure scaffolds to activate regenerative signaling in cells and tissues. Its pipeline targets neurological injuries, neuro-inflammatory diseases, and musculoskeletal disorders.
Who founded Amphix Bio?
Amphix Bio was founded by Samuel Stupp, Nick Sather, Dévora Grynspan.
How much funding has Amphix Bio raised?
Amphix Bio has disclosed $10.3M raised across 1 round.
Where is Amphix Bio headquartered?
Amphix Bio is headquartered in Chicago, US.